Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALRN-6924 in Pediatric Cancer
NCT03654716Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2018
- Primary completion
- Jul 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sulanemadlin in solid tumor, brain tumor, lymphoma and 1 more (3 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Dose Limiting Toxicity at 2 years and Toxicity by CTCAE v.5.0 at 2 years. Started Nov 2018; status: completed.
02
Drugs
sulanemadlin
03
Conditions
solid tumorbrain tumorlymphomaleukemia
Beyond the preview
Go deeper on NCT03654716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654716.